content: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                         PURSUANT TO SECTION 13 OR 15(d) OF
                             THE SECURITIES ACT OF 1934
  
          Date of report (Date of earliest event reported): August 14, 2002
                                                            ---------------
  
  
                                 CYTOGEN CORPORATION
                 (Exact Name of Registrant as Specified in Charter)
  
  
             Delaware                    000-14879                  222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction    (Commission File Number)       (IRS Employer
         of Incorporation)                                     Identification No.)
  
  
  
  600 College Road East, CN 5308, Princeton, NJ                           08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                              (Zip Code)
  
  
  
                                   (609) 750-8200
                  ------------------------------------------------
                           (Registrant's telephone number,
                                including area code)
  
  
  
            -------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
  <PAGE>
  
  
           Item 5.     Other Events.
  
       On August 14, 2002,  Cytogen  Corporation  (the  "Company")  issued a press
  release  reporting  that  it  was  notified  by the  Nasdaq  Stock  Market  Inc.
  ("Nasdaq")  regarding the Company's  non-compliance with the minimum closing bid
  price requirement  relating to Cytogen Common Stock. The Company has 90 calendar
  days or until November 12, 2002 to regain  compliance with the minimum bid price
  requirement of $1.00 per share.
  
       There can be no  assurance  that the Company  will be able to maintain  the
  listing of its Common Stock on Nasdaq  National  Market.  Such  delisting of its
  Common Stock could make it difficult for the Company to obtain future  financing
  and materially adversely affect the trading in and price of the Common Stock.
  
           Item 7.     Financial Statements, Pro Forma Financial Information
  and Exhibits.
  
           (c) Exhibits.
  
                Exhibit No.    Description
                -----------    -----------
                   99.1        Press release of the Company dated August 14, 2002
  
  
  
  <PAGE>
  
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                   Cytogen Corporation
  
  
  
                                                   By: /s/ Lawrence R. Hoffman
                                                       ---------------------------
                                                        Lawrence R. Hoffman,
                                                         Chief Financial Officer
  
  
  Date:  August 19, 2002
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form_8k-081402.txt", "description": "FORM 8-K DATED AUGUST 14, 2002", "secsgml_size_bytes": 3304}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "02742642"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                         PURSUANT TO SECTION 13 OR 15(d) OF
                             THE SECURITIES ACT OF 1934
  
          Date of report (Date of earliest event reported): August 14, 2002
                                                            ---------------
  
                                 CYTOGEN CORPORATION
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                    000-14879                  222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction    (Commission File Number)       (IRS Employer
         of Incorporation)                                     Identification No.)
  
  600 College Road East, CN 5308, Princeton, NJ                           08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                              (Zip Code)
  
                                   (609) 750-8200
                  ------------------------------------------------
                           (Registrant's telephone number,
                                including area code)
  
            -------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  Item 5.     Other Events.
  
       On August 14, 2002,  Cytogen  Corporation  (the  "Company")  issued a press
  release  reporting  that  it  was  notified  by the  Nasdaq  Stock  Market  Inc.
  ("Nasdaq")  regarding the Company's  non-compliance with the minimum closing bid
  price requirement  relating to Cytogen Common Stock. The Company has 90 calendar
  days or until November 12, 2002 to regain  compliance with the minimum bid price
  requirement of $1.00 per share.
  
       There can be no  assurance  that the Company  will be able to maintain  the
  listing of its Common Stock on Nasdaq  National  Market.  Such  delisting of its
  Common Stock could make it difficult for the Company to obtain future  financing
  and materially adversely affect the trading in and price of the Common Stock.
  
           Item 7.     Financial Statements, Pro Forma Financial Information
  and Exhibits.
  
           (c) Exhibits.
  
                Exhibit No.    Description
                -----------    -----------
                   99.1        Press release of the Company dated August 14, 2002
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                   Cytogen Corporation
  
                                                   By: /s/ Lawrence R. Hoffman
                                                       ---------------------------
                                                        Lawrence R. Hoffman,
                                                         Chief Financial Officer
  
  Date:  August 19, 2002